BNTC NASDAQ
Benitec Biopharma Inc.
1W: -6.4%
1M: -30.3%
3M: -32.0%
YTD: -23.8%
1Y: -29.6%
3Y: +233.8%
5Y: -86.7%
$8.98
-0.60 (-6.26%)
Weekly Expected Move ±8.2%
$8
$8
$9
$10
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$308.5M
52W Range8.92-16.76
Volume135,137
Avg Volume140,563
Beta0.27
Dividend—
Analyst Ratings
Company Info
CEOJerel A. Banks
Employees24
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-24
Websitebenitec.com
3940 Trust Way
Hayward, CA 94545
US
Hayward, CA 94545
US
510 780 0819
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Latest News
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Benitec GAAP EPS of -$0.98 in-line
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
60,061 Shares in Benitec Biopharma Limited $BNTC Acquired by Bank of New York Mellon Corp
AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BUCHI J KEVIN | G-Gift | 51,813 | — | 2026-06-29 |
| Friedman David Matth | A-Award | 35,000 | $11.45 | 2026-05-26 |
| Friedman David Matth | 0 | — | 2026-05-22 | |
| Mates Sharon | A-Award | 31,500 | $12.83 | 2026-01-22 |
| SUVRETTA CAPITAL MAN | P-Purchase | 65,800 | $13.44 | 2025-12-29 |